TAK
Stock Details
TAK is Takeda Pharmaceutical Company Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 15.97$. Average daily volumn in 3 months 2.68M. Market cap 51.44B
Stock symbol : TAK. Exchange : NYSE. Currency : USD Lastest price : 16.48$. Total volume : 1.67M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Takeda Pharmaceutical Company Limited (TAK)
Last Price
16.48$Change
0.13Volume
1.67M
| Previous Close | 16.35 |
| Open | 16.35 |
| Day Range | 16.37-16.50 |
| Bid | 16.46 x 4k |
| Ask | 16.47 x 2.2k |
| Volume | 1.67M |
| Average Volume | 2.68M |
| Market Cap | 51.44B |
| Beta | 0.69 |
| 52 Week Range | 12.28-16.58 |
| Trailing P/E | 24.60 |
| Foward P/E | 8.32 |
| Dividend (Yield %) | 4.03% |
| Ex-Dividend Date | 2022-09-29 |
Financial Details
Organization
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynov... ate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Market Cap:
51.44BRevenue:
3.57TTotal Assets:
13.18TTotal Cash:
849.7B
News about "Takeda Pharmaceutical Company Limited"
Takeda Pharmaceutical Co. Ltd. ADR
Source from : Wall Street Journal - 4 days ago
1 Day TAK 0.73% DJIA 0.60% S&P 500 0.16% Health Care/Life Sciences 1.19% Christophe Weber President, CEO & Representative Director Takeda Pharmaceutical Co., Ltd. Constantine Saroukos Chief ...See details»
Takeda Pharmaceutical Company Limited (TAK)
Source from : Yahoo Finance - 2 days ago
BANNOCKBURN, Ill., March 27, 2023--BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of its 200th plasma donation center in the United ...See details»
Takeda Pharmaceutical Company Limited (TAK) Stock: Understanding the Volatility
Source from : newsheater - 5 days ago
The stock of Takeda Pharmaceutical Company Limited (TAK) has gone up by 0.58% for the week, with a 7.05% rise in the past month and a 6.78% rise in the past quarter. The volatility ratio for the week ...See details»
Understanding the 1.13% Volatility Levels of Takeda Pharmaceutical Company Limited’s (TAK) Stock in the Past 30 Days
Source from : newsheater - 2 days ago
The stock of Takeda Pharmaceutical Company Limited (TAK) has gone up by 0.24% for the week, with a 7.30% rise in the past month and a 6.81% rise in the past quarter. The volatility ratio for the week ...See details»
The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership
Source from : The Business Journals - 9 days ago
Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial.See details»
BlackRock Increases Position in Takeda Pharmaceutical Company Limited (each representing 1 (TAK)
Source from : Nasdaq - 1 month ago
Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 113.75MM shares of Takeda Pharmaceutical Company Limited (each representing 1/2 of a share o (TAK).See details»
Takeda Details the Clinical Data That Led to a $4B Deal for an Autoimmune Drug
Source from : MedCity News - 11 days ago
Takeda Pharmaceutical drug TAK-279 achieved the main goal of a mid-stage clinical trial in plaque psoriasis, setting the stage for Phase 3. The Japanese pharmaceutical giant sees the small molecule as ...See details»
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Source from : Nasdaq - 2 years ago
The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...See details»
Takeda Pharmaceuticals’ $22 Million 401(k) Deal Wins Court Nod
Source from : news.bloomberglaw - 8 days ago
Takeda Pharmaceuticals USA Inc. on Friday received final approval for a $22 million class settlement with workers challenging the target date funds in their 401(k) plan.See details»
Takeda Pharmaceutical Company Limited (TKD.F)
Source from : Yahoo Finance - 2 years ago
All other current bo BANNOCKBURN, Ill., March 27, 2023--BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of its 200th plasma donation center in ...See details»
Takeda Pharmaceutical Company Limited (4502.T)
Source from : Yahoo Finance - 1 month ago
OSAKA, Japan & CAMBRIDGE, Mass., February 18, 2023--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating ...See details»
Teva Pharmaceutical Industries Ltd. ADR
Source from : Barron's - 1 year ago
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...See details»
Takeda Pharmaceutical Co. Ltd.
Source from : Wall Street Journal - 1 month ago
1 Day TKPHF -0.22% DJIA -0.71% S&P 500 -0.30% Health Care/Life Sciences -0.16% Christophe Weber President, CEO & Representative Director Takeda Pharmaceutical Co., Ltd. Constantine Saroukos Chief ...See details»
TAK Takeda Pharmaceutical Company Limited
Source from : Seeking Alpha - 1 month ago
**NM signifies a non meaningful value. A dash signifies the data is not available.See details»